News

Aruvant to Present at Investor and Scientific Conferences in October

NEW YORK and BASEL, Switzerland, Sept. 29, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced it will present at multiple conferences in...

One-time Gene Therapy for Sickle Cell Disease

Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease andβ-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning,has provided stable reductions in disease...

Aruvant Appoints Dr. Palaniappan as Chief Technology Officer

Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than 30 compounds including gene therapies for rare diseasesDr. Palaniappan will lead the manufacturing...

Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer

Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell disease administered with reduced intensity conditioning Most recently as head of clinical...

Aruvant Appoints William Chou as Chief Executive Officer

Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia Chou previously led the development and approval of Kymriah® for diffuse large B-cell lymphoma He...